← Signals · Healthcare · TSX
$HLS
HLS Therapeutics Inc.
Signal as of August 17, 2026  ·  90-day rolling window  ·  Pharmaceuticals
Confluence Score
60
out of 100  ·  Full breakdown →
Score delayed 7 days on Free  ·  See today's score — Analyst →
Signals scoring 60–74 have historically hit 49% of the time (avg +5.2% over 90 days, 1310 backtested signals). Methodology →
🔒 Risk monitoring — insider-selling & reversal warnings (Analyst)
2 open-market buys  ·  2 unique buyers  ·  $24K total Lobbying: 0 regs  ·  Contracts: 0 wins
Confluence Score
60
Unlock breakdown →
Insider Activity (90d)
2
2 buyers  ·  $24K  ·  open-market only
Current Price
$3.75
CAD  ·  5-min cache
Market Cap
$117M
CAD  ·  TMX
Lobbying & Contracts
None
0 regs  ·  0 contracts
Healthcare on Form55: 43% hit rate · -5.4% alpha vs XIU.TO · 21 closed signals Track Record →
★
Signal Analyst
The Confluence Score and insider trade feed above are free. Signal Analyst adds the full component breakdown, lobbying registrations, and contract wins — plus alerts when this company's signal moves, so you don't have to keep checking back.
Monitor — CAD $29/mo
Price Chart
12 months daily  ·  TSX:HLS
Insider Transactions
90-day window  ·  9 filings
Date Insider Role Nature Dir. Shares Buy Price Return Value
Jun 26, 2026 Millian, Craig — Comp. Grant Buy 123,000 $4.14 -9.4%  · 59d $509K
Jun 26, 2026 Hanna, John Gordon — Comp. Grant Buy 50,000 $4.14 -9.4%  · 59d $207K
Jun 26, 2026 Walsh, Brian Thomas — Comp. Grant Buy 50,000 $4.14 -9.4%  · 59d $207K
Jun 26, 2026 Lennox, Ryan Christopher — Comp. Grant Buy 35,000 $4.14 -9.4%  · 59d $145K
Jun 26, 2026 Gross, Jason — Comp. Grant Buy 12,000 $4.14 -9.4%  · 59d $50K
Jun 26, 2026 Perry, Patricia — Comp. Grant Buy 10,000 $4.14 -9.4%  · 59d $41K
Jun 26, 2026 Spence, David Andrew — Comp. Grant Buy 10,000 $4.14 -9.4%  · 59d $41K
Jun 17, 2026 Millian, Craig — Open Market Buy 2,000 $3.16 +18.7%  · 68d $6K
Jun 16, 2026 Hanna, John Gordon — Open Market Buy 4,000 $4.30 -12.8%  · 69d $17K
Score uses open-market buys only  ·  2 open-market  ·  7 plan / compensation shown but not scored  ·  Return is unrealized, to today's price; a “· Nd” mark means the 90-day window is still open (N of 90 days) — too early to judge.
Score Breakdown
Signal Analyst  ·  $29/mo
Component Points Max Detail Weight
Conviction (unique buyers)  ✓ FREE PREVIEW 25 30 2 unique buyers
Buy/sell ratio 20 100% buys (2B / 0S)
Dollar value 25 $24K
Lobbying activity 15 None
Contract wins 10 None
Insider track record 10 No track record data
Private placements 8 None
Confluence bonus 10 None
Cluster timing (velocity) 10 Tight cluster: 2+ insiders bought within ~3 days
Buy/sell reversal pattern 8 No buy/sell reversal pattern
Total 60 100
Unlock Component Detail — CAD $29/mo
Buying Insiders
Open-market · 90 days · 2 unique buyers
Insider Credibility Hit Rate Avg 90d Return Trades (eval'd) Buy Value (90d) Last Buy
Hanna, John Gordon — — — — $17K Jun 16, 2026
Millian, Craig — — — — $6K Jun 17, 2026
Credibility score: historical hit rate × avg 90d return × sample size. View full insider leaderboard →
Lobbying Registrations
OCL active  ·  none found
No active OCL lobbying registrations in the last 90 days. Analyst plan →
Government Contract Wins
90-day window  ·  none found
No government contract wins in the last 90 days. Analyst plan →
Private Placements
12 months  ·  Signal Analyst  ·  $29/mo
Private placement history, deal size, and lock-up expiry tracking. Analyst plan →
Indigenous Consultation
no records on file

No Indigenous consultation records on file for HLS.

SEDAR+ Filings
official filing registry
Form55 monitors SEDAR+ filing alerts and newswire announcements for Technical Reports and material changes. Search SEDAR+ →
Short Interest
CIRO  ·  Aug 15, 2026
Shares short
10,937
Net change
+1,220 (+12.6%)
History
Aug 15: 10,937
Jul 31: 9,717
Jul 15: 1,149
Jun 30: 302,313
Jun 15: 1,819
May 31: 6,862
Aggregate short position from CIRO's Consolidated Short Position Report (published twice monthly).
Form55 provides data and analysis for informational purposes only. Nothing on this site constitutes investment advice or a recommendation to buy or sell any security. Past performance is not indicative of future results.